SCHEMBL3517626

SCHEMBL3517626

CNCC1(c2ccc(Cl)c(Cl)c2)CCC(C)(O)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 20/20 1.00
SLC6A3 Q01959 20/20 1.00
SLC6A2 P23975 5/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13280098 1.00 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL13468192 1.00 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL3517957 0.86 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL3521921 0.84 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL3521466 0.84 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL5141154 0.84 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL5476630 0.83 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL17999748 0.83 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL3518594 0.83 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2
SCHEMBL5476626 0.83 SLC6A4 (1.00) SLC6A4SLC6A3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101394847-B Cycloalkylamines as monoamine reuptake inhibitors 塞普拉柯公司 2017-05-24 CN claimed
EP-1976513-B1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC (US) 2016-08-24 EP claimed
US-8877975-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2014-11-04 US claimed
WO-2012142067-A2 FORMULATIONS, SALTS, AND SOLID FORMS OF SUBSTITUTED CYCLOHEXYLMETHANAMINES, PROCESSES FOR PREPARATION, AND USES THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-10-18 WO claimed
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2010-07-29 US claimed
US-10562878-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARAMCEUTICALS INC. (US) 2020-02-18 US disclosed
US-9868718-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2018-01-16 US disclosed
EP-1976513-B1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC (US) 2016-08-24 EP disclosed
US-20150126511-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2015-05-07 US disclosed
US-8877975-B2 Cycloalkylamines as monoamine reuptake inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2014-11-04 US disclosed
US-20140086995-A1 POLYMER MICROSPHERE COMPOSITIONS FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS NATIONAL SCIENCE FOUNDATION 2014-03-27 US disclosed
WO-2012142067-A2 FORMULATIONS, SALTS, AND SOLID FORMS OF SUBSTITUTED CYCLOHEXYLMETHANAMINES, PROCESSES FOR PREPARATION, AND USES THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-10-18 WO disclosed
WO-2012142328-A2 POLYMER MICROSPHERE COMPOSITIONS FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS RATNER BUDDY D (US) 2012-10-18 WO disclosed
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SUNOVION PHARMACEUTICALS INC. 2010-07-29 US disclosed
EP-1976513-A2 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS Sepracor, Inc. (US) 2008-10-08 EP disclosed
US-20070203111-A1 Cycloalkylamines as monoamine reuptake inhibitors SEPRACOR INC. (US) 2007-08-30 US disclosed
WO-2007081857-A2 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SEPRACOR INC. (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150126511-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 SLC6A4 5/4885SLC6A3 4/4885SLC6A2 2/4885
US-20140086995-A1 POLYMER MICROSPHERE COMPOSITIONS FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS ACTB, PGF, HSP90AB1 SLC6A4 4573/4885SLC6A3 4614/4885SLC6A2 4169/4885
US-20070203111-A1 Cycloalkylamines as monoamine reuptake inhibitors SLC18A2, SLC6A2, SLC18A3 SLC6A4 5/4885SLC6A3 4/4885SLC6A2 2/4885
US-20100190861-A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 SLC6A4 5/4885SLC6A3 4/4885SLC6A2 2/4885
US-10562878-B2 Cycloalkylamines as monoamine reuptake inhibitors SLC18A2, SLC6A2, SLC18A3 SLC6A4 5/4885SLC6A3 4/4885SLC6A2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.